title: Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment.
abstract: Major depressive disorder (MDD) often occurs during pegylated IFN-alpha2 (IFN-alpha) treatment. Identifying who is at risk for MDD in this population is essential, and epidemiological studies suggest that sleep may be related to depression risk. Controlling for pre-existing depression symptoms, we therefore examined whether sleep quality prior to IFN-alpha treatment would predict subsequent MDD incidence during IFN-alpha treatment. Adults with hepatitis C but without current clinical MDD (n=86) were evaluated prior to IFN-alpha treatment and then prospectively monitored during treatment using self-report measures of sleep quality (PSQI), depression (BDI), and anger and irritability (AIAQ), as well as with Structured Clinical Interviews for DSM-IV Axis I Disorders (SCID-I). During IFN-alpha treatment, 19% developed MDD, 19% developed subsyndromal depression with irritability, and one developed mania. Controlling for baseline depression symptoms and past history of depression, patients with worse sleep quality (PSQI > or = 10) prior to treatment had a significantly shorter time until they developed MDD or any severe psychiatric problem. These findings may have important implications for understanding, predicting, and possibly preventing depression, particularly in individuals treated with IFN-alpha.
authors.affiliation: Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. franzenpl@upmc.edu
authors.forename: Peter L
authors.initials: PL
authors.lastname: Franzen
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Buysse
authors.forename: Mordechai
authors.initials: M
authors.lastname: Rabinovitz
authors.forename: Bruce G
authors.initials: BG
authors.lastname: Pollock
authors.forename: Francis E
authors.initials: FE
authors.lastname: Lotrich
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D003865:Major Depressive Disorder / Q000145:classification / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006306:Health Surveys; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D016898:Interferon-alpha / Q000009:adverse effects*; D007508:Irritable Mood / Q000502:physiology*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012893:Sleep Wake Disorders / Q000139:chemically induced*; D013997:Time Factors
chemical_list: D007155:Immunologic Factors; D016898:Interferon-alpha
references.citation: Am J Psychiatry. 1995 Jul;152(7):967-72
references.pmid: 7793466
references.citation: Psychiatry Res. 1989 May;28(2):193-213
references.pmid: 2748771
references.citation: N Engl J Med. 2001 Mar 29;344(13):961-6
references.pmid: 11274622
references.citation: Sleep Med Rev. 2000 Jun;4(3):253-262
references.pmid: 12531168
references.citation: J Clin Psychiatry. 2005 Jan;66(1):41-8
references.pmid: 15669887
references.citation: Acta Neurol Scand. 2004 Jul;110(1):6-13
references.pmid: 15180801
references.citation: Am J Psychiatry. 2008 Dec;165(12):1543-50
references.pmid: 18765482
references.citation: J Affect Disord. 2007 Nov;103(1-3):83-90
references.pmid: 17292481
references.citation: Brain Behav Immun. 2004 May;18(3):205-13
references.pmid: 15050647
references.citation: J Affect Disord. 2003 Sep;76(1-3):255-9
references.pmid: 12943956
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: Am J Epidemiol. 1997 Jul 15;146(2):105-14
references.pmid: 9230772
references.citation: Brain Behav Immun. 2003 Feb;17 Suppl 1:S119-24
references.pmid: 12615197
references.citation: J Clin Psychiatry. 1992 Jun;53 Suppl:37-41
references.pmid: 1613018
references.citation: N Engl J Med. 1999 Apr 29;340(17):1370
references.pmid: 10223879
references.citation: J Psychosom Res. 2007 Aug;63(2):131-5
references.pmid: 17662748
references.citation: Mol Psychiatry. 2002;7(9):942-7
references.pmid: 12399946
references.citation: Psychosomatics. 2003 Mar-Apr;44(2):104-12
references.pmid: 12618532
references.citation: Biol Psychiatry. 1996 Mar 15;39(6):411-8
references.pmid: 8679786
references.citation: Br J Psychiatry. 1989 Feb;154:201-6
references.pmid: 2775946
references.citation: World J Gastroenterol. 2005 Mar 28;11(12):1769-74
references.pmid: 15793861
references.citation: Neuropsychopharmacology. 2001 Nov;25(5 Suppl):S45-9
references.pmid: 11682273
references.citation: J Neuropsychiatry Clin Neurosci. 1991 Spring;3(2):S44-51
references.pmid: 1821222
references.citation: J Clin Psychiatry. 2003 Jun;64(6):708-14
references.pmid: 12823087
references.citation: J Psychiatr Res. 1997 May-Jun;31(3):377-81
references.pmid: 9306295
references.citation: Psychiatry Res. 1992 Mar;41(3):237-48
references.pmid: 1594710
references.citation: AIDS. 2005 Oct;19 Suppl 3:S174-8
references.pmid: 16251815
references.citation: Psychosomatics. 2004 Mar-Apr;45(2):176
references.pmid: 15016930
references.citation: CNS Drugs. 2005;19(2):105-23
references.pmid: 15697325
references.citation: Aliment Pharmacol Ther. 2006 Oct 15;24(8):1223-30
references.pmid: 17014581
references.citation: J Clin Psychiatry. 2005 Aug;66(8):1050-7
references.pmid: 16086622
references.citation: Behav Sleep Med. 2006;4(2):104-13
references.pmid: 16579719
references.citation: Biol Psychiatry. 2006 Jun 1;59(11):1052-60
references.pmid: 16581036
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2002 May;26(4):731-46
references.pmid: 12188106
references.citation: Am J Psychiatry. 2004 Jan;161(1):19-24
references.pmid: 14702243
references.citation: Sleep. 2008 Apr;31(4):473-80
references.pmid: 18457234
references.citation: N Engl J Med. 1998 Nov 19;339(21):1485-92
references.pmid: 9819446
references.citation: JAMA. 1989 Sep 15;262(11):1479-84
references.pmid: 2769898
references.citation: Lancet. 2001 Sep 22;358(9286):958-65
references.pmid: 11583749
references.citation: Endocrinol Metab Clin North Am. 2002 Mar;31(1):15-36
references.pmid: 12055986
references.citation: J Clin Endocrinol Metab. 2004 May;89(5):2119-26
references.pmid: 15126529
references.citation: Sleep. 1996 May;19(4):318-26
references.pmid: 8776790
references.citation: J Psychosom Res. 2002 Sep;53(3):737-40
references.pmid: 12217446
references.citation: Arthritis Rheum. 2005 Apr 15;53(2):272-8
references.pmid: 15818653
references.citation: J Clin Gastroenterol. 2006 Apr;40(4):322-35
references.pmid: 16633105
references.citation: Biol Psychiatry. 2009 Feb 15;65(4):344-8
references.pmid: 18801474
references.citation: J Affect Disord. 2004 Oct 15;82(2):175-90
references.pmid: 15488246
references.citation: Sleep Med. 2007 Apr;8(3):198-208
references.pmid: 17368098
references.citation: J Clin Oncol. 2000 Jun;18(11):2316-26
references.pmid: 10829053
references.citation: Dialogues Clin Neurosci. 2008;10(4):473-81
references.pmid: 19170404
references.citation: Int J Neurosci. 2004 Feb;114(2):245-56
references.pmid: 14702212
references.citation: Ann Clin Psychiatry. 2006 Jan-Mar;18(1):49-56
references.pmid: 16517453
references.citation: Eur J Gastroenterol Hepatol. 2000 May;12(5):505-9
references.pmid: 10833092
references.citation: Brain Behav Immun. 2001 Sep;15(3):199-226
references.pmid: 11566046